Business Context and Reporting Period
This Form 8-K Current Report, dated December 2, 2020, is filed by NanoVibronix, Inc. (trading symbol: NAOV), a Delaware corporation and emerging growth company. The report details a material definitive agreement entered into on December 2, 2020, regarding a private placement of equity securities. The transaction closed on December 7, 2020.
Key Financial Metrics
The filing discloses the following financial details regarding the private placement:
- Gross Proceeds: Approximately $6.0 million.
- Net Proceeds: Approximately $5.4 million after deducting placement agent fees, management fees, and estimated offering expenses.
- Securities Issued:
- 5,914,285 shares of Common Stock at $0.70 per share.
- Pre-funded warrants to purchase up to 2,657,144 shares of Common Stock at $0.699 per warrant.
- Placement Agent Compensation:
- Cash fee: 7.5% of gross proceeds.
- Management fee: 1.0% of gross proceeds.
- Non-accountable expense allowance: $85,000.
- Warrants: 642,857 warrants (7.5% of aggregate shares placed) with an exercise price of $0.875 per share.
The filing does not provide data on revenue, profit, operating cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the increase in capitalization and cash liquidity resulting from the private placement. The company issued new equity and pre-funded warrants to institutional and accredited investors. The filing does not provide comparative financial data against prior periods to quantify changes in revenue or profitability.
Guidance, Outlook, and Risks
Use of Proceeds: The company intends to use the net proceeds for general corporate purposes.
Registration Rights: The company agreed to file a registration statement on Form S-3 by December 12, 2020, to register the resale of the shares and shares issuable upon exercise of the pre-funded warrants.
Ownership Limitations: Holders of pre-funded warrants are subject to beneficial ownership limitations of 4.99% (or 9.99% at election) unless they provide 61 days' prior notice to increase the limit.
Risks and Contingencies: The securities were offered pursuant to exemptions from registration under Section 4(a)(2) and Rule 506(b) of the Securities Act of 1933. The filing notes that representations and warranties are subject to limitations agreed upon by the contracting parties.
Investor Verification Checklist
- Verify the closing date of the private placement (December 7, 2020) and the actual receipt of net proceeds.
- Confirm the filing of the Form S-3 registration statement by the December 12, 2020 deadline.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and termination provisions.
- Assess the dilution impact of the 5,914,285 common shares and 2,657,144 pre-funded warrants on existing shareholders.
- Monitor the exercise of the placement agent warrants (642,857 shares) at the $0.875 strike price.